UK Markets closed

PTC Therapeutics, Inc. (PTCT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
36.84-0.36 (-0.97%)
As of 12:57PM EDT. Market open.

PTC Therapeutics, Inc.

100 Corporate Court
South Plainfield, NJ 07080
United States
908 222 7000
https://www.ptcbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees988

Key executives

NameTitlePayExercisedYear born
Dr. Matthew B. Klein F.A.C.S., M.D., M.S.CEO & Director1.24MN/A1972
Dr. Stuart W. Peltz Ph.D.Co-Founder, Senior Consultant & Member of Scientific Advisory Board796.9kN/A1960
Dr. Allan Steven Jacobson Ph.D.Co-Founder, Chairman of Scientific Advisory Board & Independent Director145kN/A1946
Mr. Pierre Gravier M.S.Chief Financial Officer619.92kN/A1986
Mr. Mark Elliott BouldingExecutive VP & Chief Legal Officer761.94k1.27M1961
Mr. Eric PauwelsChief Business Officer761.18kN/A1961
Dr. Lee Golden M.D., Ph.D.Executive VP & Chief Medical Officer716.78kN/A1968
Ms. Christine UtterSenior VP, Chief Accounting Officer & Head of People Services595.54k995.57k1978
Dr. Neil Almstead Ph.D.Chief Technical Operations Officer829.97kN/A1967
Alex KaneInvestor Relations OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Corporate governance

PTC Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 5. The pillar scores are Audit: 7; Board: 2; Shareholder rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.